Skip to main content
. 2009 Nov;11(7):592–599. doi: 10.1111/j.1477-2574.2009.00106.x

Figure 6.

Figure 6

Landmark analysis for hazard ratio for disease-specific survival (DSS) by peri-operative irinotecan or oxaliplatin (iri/oxal) therapy. Post-resection chemotherapy was truncated at 6 months and all patients with follow-up time less than 6 months were excluded form this landmark analysis. The total length of iri/oxal chemotherapy was recalculated as the sum of the pre-resection chemotherapy and truncated post-resection chemotherapy. P= 0.27